Find, compare & contact
Fenpyroximate
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Fenpyroximate API 134098-61-6?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Fenpyroximate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Fenpyroximate
- Synonyms:
- Fenpryroximate , Fenpyroximate (z,e) , Fujimite , Sequel
- Cas Number:
- 134098-61-6
- DrugBank number:
- DB16164
- Unique Ingredient Identifier:
- 9W557V4RYA
General Description:
Fenpyroximate, identified by CAS number 134098-61-6, is a notable compound with significant therapeutic applications. Fenpyroximate is under investigation in clinical trial NCT02533336 (The Effectiveness of Non-pyrethroid Insecticide-treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania).
Categories:
Fenpyroximate is categorized under the following therapeutic classes: Acids, Carbocyclic, Benzene Derivatives, Electron Transport Complex I, antagonists & inhibitors. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Fenpyroximate is a type of Antimalarial
The Antimalarial category of pharmaceutical APIs encompasses a range of active ingredients used in the development of drugs to treat and prevent malaria, a life-threatening infectious disease caused by the Plasmodium parasite. These APIs are crucial in formulating effective antimalarial medications.
One widely used API in this category is Artemisinin, derived from the Artemisia annua plant. It exhibits potent antimalarial properties and is a key component in various combination therapies. Another prominent API is Chloroquine, an aminoquinoline compound that has been historically used as a primary treatment for malaria. However, due to emerging drug resistance, alternative APIs like Mefloquine and Quinine have gained prominence.
These APIs work by interfering with the life cycle of the Plasmodium parasite. They inhibit various stages of parasite development, such as preventing the replication of the parasite's DNA and disrupting its metabolic processes. By targeting the parasite, antimalarial APIs help to control and eliminate the infection, reducing the severity of symptoms and preventing complications.
The development and production of high-quality antimalarial APIs require stringent quality control measures to ensure their safety and efficacy. Pharmaceutical companies adhere to strict regulations and guidelines to guarantee the purity, stability, and bioavailability of these APIs. Additionally, ongoing research aims to discover new antimalarial APIs and formulations to combat drug resistance and improve treatment outcomes.
In conclusion, the Antimalarial category of pharmaceutical APIs plays a vital role in the formulation of drugs used to treat and prevent malaria. These APIs, such as Artemisinin, Chloroquine, Mefloquine, and Quinine, effectively target the Plasmodium parasite, aiding in the management and eradication of malaria infections.
